Navigation Links
Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Date:10/14/2010

FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA).  The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.  The implementation of the REMS is a result of FDA's identification in 2008 of an increased risk of suicidal thoughts and behavior with the class of antiepileptic drugs (AEDs) which includes GABITRIL.  The current product labeling already contains a warning that includes this risk.  The addition of a Medication Guide for patients and ongoing assessment of the REMS program is consistent with the company's commitment to safe and appropriate use of its medications.  

The GABITRIL Medication Guide will be available on the product website, www.gabitril.com, and will be dispensed with every prescription.  The three-pronged REMS assessment plan will be implemented on an ongoing basis to evaluate (1) patients' understanding of the potential serious risks associated with the medication; (2) the distribution and dispensing of the Medication Guide; and (3) adherence to distribution and dispensing requirements as well as corrective actions taken to address noncompliance.  In accordance with the approved REMS, the company is currently updating all labeling related to GABITRIL to include the Medication Guide.

Additional information on GABITRIL is available at www.GABITRIL.com or at 1-800-896-5855.  More information on Cephalon and its products is available at www.cephalon.com.  

About GABITRILGABITRIL is ind
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 ... pressphoto agency ( http://www.epa.eu ) - ... lancio della nuova generazione di OASIS* all,ECR 2015. Si ... ad alto campo da 1.2 T che migliora la ... nuovo traguardo nell,attenzione al comfort del paziente. Le nuove ...
(Date:3/5/2015)... DUBLIN and HAMPTON, N.J. ... (NYSE: MNK ), a leading global ... care company, announced today that they have entered into ... will acquire Ikaria, Inc. from a Madison Dearborn ... $2.3 billion. Subject to customary closing ...
(Date:3/5/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... announced today that Atlanta -based Shepherd ... spinal cord injury and brain injury, has commenced enrollment ... progenitor cells) in newly injured patients with sensory and ... The Phase 1/2a trial follows the successful completion ...
Breaking Medicine Technology:Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4
(Date:3/5/2015)... 2015 The Maricopa Community Colleges ... to the Arizona economy each year, according to a ... Economic Value of Maricopa County Community College District, summarizes ... district in fiscal year 2013-2014. , The analysis ... (EMSI), an organization that specializes in providing economic impact ...
(Date:3/5/2015)... SuperCloset has released a new video series called ... viewers everything they need to know about how to grow ... you from seed all the way through harvest, and covers ... prune Grow Like a SuperPro will help take the guesswork ... download for a special introductory price of $19.95. Or you ...
(Date:3/5/2015)... 2015 TCS Healthcare Technologies (TCS), a ... population health management arena, is pleased to announce a ... ACUITY Advanced Care™ (ACUITY) version 7.20. The session will ... the advantages of automation. , The webinar, scheduled for ... led by Jeff Frater, RN, BSN, Director of Partner ...
(Date:3/5/2015)... PA (PRWEB) March 05, 2015 ... leader in healthcare communications and education, announced today ... (AMP), the nation’s only medical conference designed ... limb ischemia and lower limb amputation due to ... growing family of innovative, evidence-based publications and CME ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
Breaking Medicine News(10 mins):Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4
... , , NAPLES, Fla., Sept. 3 ... the elderly and is projected to increase in prevalence over the ... for treatments that will prevent or reverse the now-inexorable course of ... expensive and complex, many researchers are focusing on botanical extracts whose ...
... To avoid injuries, watch backpack weight and fit, expert suggests, ... be a great help to school children, but it needs ... professionals say. , "If too heavy or worn incorrectly, ... pain," Paula Kramer, who chairs the occupational therapy department at ...
... , FRANKLIN, Mass., Sept. 3 ... ECTE), a diabetes management company developing the ... continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep ... that Patrick T. Mooney, M.D., Chairman and Chief Executive ...
... HARBIN, China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- China Sky ... (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical ... ("PRC"), today announced that the,Company has finished the required ... submitted application to the State Food and Drug Administration,(SFDA) ...
... MOUNTAIN VIEW, Calif., Sept. 3 An expanding ... the U.S. bone and joint health ingredients market. Consumers ... wellness quotient and have strong scientific backup. The rise ... need for well-researched ingredients that deliver tangible advantages. , ...
... , , CARLSBAD, Calif., ... leader in antisense therapeutics, today announced that management will present a company ... 9, 2009, at 11:30 a.m. ET at the Boston Four Seasons Hotel. ... will be available on the "Investors & Media" section of the Company,s ...
Cached Medicine News:Health News:HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid-Beta Accumulation, a Hallmark of Alzheimer's Disease 2Health News:HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid-Beta Accumulation, a Hallmark of Alzheimer's Disease 3Health News:Take the Load Off Your Child's Back 2Health News:Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference 2Health News:China Sky One Medical, Inc. Submits Application to Perform Clinical Trials for Two New Eye Drugs to SFDA 2Health News:China Sky One Medical, Inc. Submits Application to Perform Clinical Trials for Two New Eye Drugs to SFDA 3Health News:Aging Population, Heightened Consumer Awareness Propel U.S. Bone and Joint Health Ingredients, Says Frost & Sullivan 2Health News:Aging Population, Heightened Consumer Awareness Propel U.S. Bone and Joint Health Ingredients, Says Frost & Sullivan 3Health News:Aging Population, Heightened Consumer Awareness Propel U.S. Bone and Joint Health Ingredients, Says Frost & Sullivan 4Health News:Isis Pharmaceuticals to Present at Thomas Weisel Partners' Healthcare Conference 2009 2
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
...
Medicine Products: